@article{AOL5567,
author = {Astrid Pavlovsky},
title = {Better understanding and new challenges in high grade lymphomas},
journal = {Annals of Lymphoma},
volume = {3},
number = {0},
year = {2019},
keywords = {},
abstract = {Diffuse large B-cell lymphoma (DLBCL), comprise the most commonly diagnosed non-Hodgkin lymphoma. Approximately 60–65% of patients can be cured with standard front-line therapy R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone). However, the progress in the understanding of the disease has led us to appreciate its underlying heterogeneity.},
issn = {2616-2695}, url = {https://aol.amegroups.org/article/view/5567}
}